No products in the cart.
Pre-made Bafisontamab benchmark antibody ( Whole mAb, anti-EGFR;MET therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-656
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bafisontamab biosimilar, Whole mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Bafisontamab biosimilar, Whole mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody |
|---|---|
| INN Name | Bafisontamab |
| Target | EGFR,MET |
| Format | Bispecific Mixed mAb and Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G1;na |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | 5sx4:HL/5sx5:JK;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | EpimAb Biotherapeutics |
| Conditions Approved | NA |
| Conditions Active | Non-small cell lung cancer,Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EGFR,MET |
| Package |
Previous slide
Next slide
